Literature DB >> 20066894

Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.

Woong Ju1, Byong Chul Yoo, Il-Jin Kim, Jae Weon Kim, Seung Cheol Kim, Hyo Pyo Lee.   

Abstract

A major obstacle in treatment of epithelial ovarian cancer is chemoresistance. The aim of this study was to determine whether distinct gene expression profiles are associated with chemoresistance in epithelial ovarian carcinoma. We performed global gene expression analysis in 13 primary epithelial ovarian cancer tissues including 5 primary chemosensitive tumors and 8 primary chemoresistant tumors using Affymetrix HGU133A microarray. The gene expression patterns of chemosensitive tumors were compared with those of chemoresistant tumors using fold change. Validity of microarray results was examined by semiquantitative RT-PCR. We identified over 320 genes differentially expressed in chemoresistant epithelial ovarian cancer (> or = twofold). Upregulated genes in chemoresistant tumors included cell cycle regulating genes (TOP2A, BCAT1, CDCA8, CCNA2, CENPE), and genes with previously known mechanisms in tumorigenesis (S100A9, APOA1, RNF125, IFI16). Downregulated genes in chemoresistant tumors included genes related to cell adhesion (MUC5B, CITED2), transcription regulating genes (FOXD1, MAD1L1, PAX2), genes involving signal transduction (SOSTDC1, SNX1, SFRP1, FOXA2, PLK2), and stress protein gene (TP53AP1). These data show that gene expression profiling can discriminate primary chemoresistant from primary chemosensitive ovarian cancers. This type of molecular profiling could provide a basis for additional functional studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20066894     DOI: 10.3727/096504009789954672

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  35 in total

1.  Prioritization of SNPs for genome-wide association studies using an interaction model of genetic variation, gene expression, and trait variation.

Authors:  Hyojung Paik; Junho Kim; Sunjae Lee; Hyoung-Sam Heo; Cheol-Goo Hur; Doheon Lee
Journal:  Mol Cells       Date:  2012-03-28       Impact factor: 5.034

2.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

3.  Transcriptional activation of human CDCA8 gene regulated by transcription factor NF-Y in embryonic stem cells and cancer cells.

Authors:  Can Dai; Cong-Xiu Miao; Xiao-Ming Xu; Lv-Jun Liu; Yi-Fan Gu; Di Zhou; Lian-Sheng Chen; Ge Lin; Guang-Xiu Lu
Journal:  J Biol Chem       Date:  2015-07-13       Impact factor: 5.157

Review 4.  The multisystemic functions of FOXD1 in development and disease.

Authors:  Paula Quintero-Ronderos; Paul Laissue
Journal:  J Mol Med (Berl)       Date:  2018-06-29       Impact factor: 4.599

5.  The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.

Authors:  V Thewes; R Simon; M Hlevnjak; M Schlotter; P Schroeter; K Schmidt; Y Wu; T Anzeneder; W Wang; P Windisch; M Kirchgäßner; N Melling; N Kneisel; R Büttner; U Deuschle; H P Sinn; A Schneeweiss; S Heck; S Kaulfuss; H Hess-Stumpp; J G Okun; G Sauter; A E Lykkesfeldt; M Zapatka; B Radlwimmer; P Lichter; M Tönjes
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

6.  RNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrity.

Authors:  Brian D Yard; Nicole M Reilly; Michael K Bedenbaugh; Douglas L Pittman
Journal:  DNA Repair (Amst)       Date:  2016-04-21

Review 7.  Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Authors:  Helen M Coley; Eleftheria Hatzimichael; Sarah Blagden; Iain McNeish; Alastair Thompson; Tim Crook; Nelofer Syed
Journal:  Oncotarget       Date:  2012-01

8.  Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.

Authors:  B Taylor-Harding; H Agadjanian; H Nassanian; S Kwon; X Guo; C Miller; B Y Karlan; S Orsulic; C S Walsh
Journal:  Br J Cancer       Date:  2011-12-13       Impact factor: 7.640

9.  Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.

Authors:  Björg Kristjansdottir; Kristina Levan; Karolina Partheen; Elisabet Carlsohn; Karin Sundfeldt
Journal:  Clin Proteomics       Date:  2013-04-04       Impact factor: 3.988

10.  Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.

Authors:  Yong Han; Hao Huang; Zhen Xiao; Wei Zhang; Yanfei Cao; Like Qu; Chengchao Shou
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.